Meridian Growth Fund’s second-quarter 2025 investor letter reported a 4.10% return, compared to the Russell 2500 Growth Index’s 11.31% return. The fund’s top five holdings can be found in the letter, which can be downloaded online. U.S. equity markets saw a 23% increase during the quarter, closing at record highs.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was highlighted in Meridian Growth Fund’s investor letter. The San Diego-based biopharmaceutical company saw a one-month return of 11.11% and a 12.32% gain over the last 52 weeks. As of August 11, 2025, the stock closed at $62.89 per share with a market capitalization of $7.356 billion.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a leading drug delivery platform company with its ENHANZE® technology, reducing treatment burden for patients and easing capacity constraints for healthcare providers. Shares declined due to potential Medicare price negotiation changes. Despite this, the company continues to offer advantages in drug delivery. Hedge funds held 31 portfolios of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter of 2025, with a 41% year-over-year revenue increase.

Read more at Yahoo Finance: Here’s Why Halozyme Therapeutics (HALO) Traded Town in Q2